uniQure closes sale of Lexington facility to Genezen for $25M; $40M annual cash burn savings

uniQure N.V.

Sold Lexington, MA manufacturing facility to Genezen for $12.5M in Series C stock and $12.5M convertible note (total $25M).
Prepaid $50M of $100M Hercules debt; remaining $50M matures Jan 2027; expects $40M annual reduction in cash burn.
COO Pierre Caloz exits as role eliminated; Amin Abujoub appointed Chief Technical Operations Officer.
CEO Matt Kapusta joins Genezen board; Genezen to supply HEMGENIX under commercial supply agreement.
Transaction closed July 22, 2024; uniQure becomes meaningful shareholder in Genezen.

item 1.01 item 2.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Pierre Caloz

Chief Operating Officer

QURE · uniQure N.V.

Effective: 2024-07-22
Filed: July 23, 2024, 7:59 PM ET

In connection with the closing of the Lexington Transaction, on July 22, 2024, the Company notified Pierre Caloz, the Company’s Chief Operating Officer, that his employment was being terminated consistent with the terms of the employment agreement by and between uniQure biopharma B.V. and Mr. Caloz, dated May 17, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Pierre Caloz was terminated as Chief Operating Officer at uniQure N.V..

Action: terminated
Role: Chief Operating Officer

Exact text from the filing

In connection with the closing of the Lexington Transaction, on July 22, 2024, the Company notified Pierre Caloz, the Company’s Chief Operating Officer, that his employment was being terminated consistent with the terms of the employment agreement by and between uniQure biopharma B.V. and Mr. Caloz, dated May 17, 2021.

View on SEC.gov

uniQure N.V. filing history →

Source: SEC EDGAR

accession 0001558370-24-009957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.